Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Encouraging early detection and breaking the silence around men’s health
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
The company is bringing precision therapies for gynaecological cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Subscribe To Our Newsletter & Stay Updated
